Illumina, Inc.
Illumina Announces Spin-Off Distribution Dates for GRAIL Shares
Summary
On June 3, 2024, Illumina, Inc. announced via an 8-K/A filing that the distribution of at least 85.5% of GRAIL, LLC shares to Illumina shareholders as a pro rata dividend is expected to be effective at 12:01 A.M. New York City time on June 24, 2024. From June 12, 2024, until the Distribution Date, GRAIL shares will trade on a 'when-issued' basis on Nasdaq under the symbol 'GRALV'. After the Distribution Date, on June 25, 2024, GRAIL shares will begin regular trading on Nasdaq under the symbol 'GRAL'. During this period, Illumina shares will trade in two markets: regular way under the symbol 'ILMN' and ex-distribution under the symbol 'ILMNV'. After the Distribution Date, Illumina shares will trade under the symbol 'ILMN' only.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement